Grünenthal agrees acquisition of Bayer cancer drug Stivarga for up to €375m
Grünenthal has agreed to acquire Bayer's established oncology medicine Stivarga in a transaction worth up to €375 million.
The acquisition gives Grünenthal global rights to regorafenib, which is approved in more than 90 markets for indications including metastatic colorectal cancer, gastrointestinal stromal tumours and hepatocellular carcinoma.
The transaction expands Grünenthal's portfolio of established medicines while allowing Bayer to transfer a mature oncology asset to a company focused on managing and commercialising established products.
Field | Content |
Alert Type | Deal |
Companies | Grünenthal; Bayer |
Deal Type | Pharmaceutical asset acquisition |
Asset or Company | Stivarga (regorafenib) |
Therapy Area(s) | Oncology; colorectal cancer; gastrointestinal stromal tumours; hepatocellular carcinoma |
Technology or Modality | Oral multikinase inhibitor |
Deal Value | Up to €375 million |
Geography | Global |
What Happened | Grünenthal agreed to acquire Bayer's oncology medicine Stivarga and associated global rights for up to €375 million. |
Why It Matters | The transaction transfers a globally established oncology medicine approved across multiple tumour types and significantly expands Grünenthal's mature-product portfolio. |
Supporting Context | Stivarga is marketed in more than 90 countries and is used in metastatic colorectal cancer, gastrointestinal stromal tumours and hepatocellular carcinoma. |
Strategic Rationale | Grünenthal gains a sizeable established oncology asset while Bayer streamlines its portfolio and transfers lifecycle management to a specialist in established medicines. |
Potential Impact | The deal broadens Grünenthal's commercial footprint and adds a significant oncology revenue stream to its portfolio. |
Key Takeaway | Grünenthal is acquiring Bayer's Stivarga franchise for up to €375 million. |
What to Watch | Transaction completion, transfer of commercial operations and Grünenthal's strategy for lifecycle management of Stivarga. |
Primary Source | Grünenthal |
Relevant Date | 21 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios